Navigation Links
AviaraDx Announces CAP Accreditation of Its Laboratory Operations
Date:10/1/2007

CARLSBAD, Calif., Oct. 1 /PRNewswire/ -- AviaraDx announced today that the company's Carlsbad, CA, CLIA laboratory operation has received its College of American Pathology (CAP) accreditation. The laboratory offers two new molecular oncology tests to hospitals and physicians across the United States.

CancerTYPE ID(TM) is a 92-gene expression assay capable of classifying 39 tumor types.

CancerTYPE ID(TM) provides a molecular classification of metastatic cancer and guides the physician in differential diagnosis and identification of the primary tumor site. When used early in the cancer classification process, CancerTYPE ID is a powerful tool to quickly determine the likely primary tumor site, focusing the selection of confirmatory immunohistological and imaging procedures.

AviaraDx' H/I(TM) (HOXB13/IL17BR) test is a molecular extension of estrogen receptor (ER) testing and represents a significant improvement when assessing a patient's risk of breast cancer recurrence and the likely benefit from endocrine therapy. The H/I(TM) test is used to stratify ER+, node-negative breast cancer patient into high and low risk of recurrence as well as to predict response to endocrine therapy. Both HOXB13 and IL17BR biomarkers are controlled by estrogen and provide novel information about estrogen signaling in ER+ breast cancer.

The AviaraDx CLIA laboratory enables clinical and research laboratories, physicians, and pharmaceutical companies to incorporate these innovative molecular oncology tests into clinical practice. "We are very excited about receiving CAP accreditation, ensuring that our new molecular oncology tests meet the highest quality standards in the clinical laboratory industry", stated Antonius Schuh, Ph.D., CEO of AviaraDx. "Our mission is to continue to bring novel molecular oncology assays to physicians and patients, which answer unmet clinical needs in cancer care."

About AviaraDx

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will eventually provide information critical to predict treatment response to a given therapeutic regimen.

AviaraDx offers diagnostic tests to qualified physicians or laboratories through its certified CLIA laboratory service operations. The company's first diagnostic test offerings are based on its proprietary technologies used in molecular classification of metastatic cancer, CancerTYPE ID(TM), and its H/I(TM) (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.

CONTACT:

Antonius Schuh, Ph.D.

Chief Executive Officer of AviaraDx, Inc.

+1 (760) 579 0500

aschuh@aviaradx.com


'/>"/>
SOURCE AviaraDx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):